

| | | | |
|---|----------------------------------|---|------------------------|
| CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) | | | |
| Applicant(s): Lowe, et al. | | Docket No. 2003B126 | |
| Application No. 10/720,607 | Filing Date November 24, 2003 | Examiner Unassigned | Group Art Unit 1764 |
| Invention: Catalyst and Process for Selective Hydrogenation | | RECEIVED CENTRAL FAX CENTER AUG 24 2004 | |
| OFFICIAL | | | |
| I hereby certify that this <u>Information Disclosure Statement, Form 1449 and 2 References (39 pgs.)</u> <small>(Identify type of correspondence)</small> | | | |
| is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u>) | | | |
| on <u>August 24, 2004</u> <small>(Date)</small> | | | |
| <u>Tracy N. Keyes</u> <small>(Typed or Printed Name of Person Signing Certificate)</small>  <small>(Signature)</small> | | | |
| Note: Each paper must have its own certificate of mailing. | | | |

| | | |
|--|--|--|
| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d) | | Attny. Docket No. 2003B126 |
| In Re Application of: Lowe et al. | | |
| U.S. Serial No. 10/720,607 | Filing Date November 24, 2003 | Examiner Not Assigned |
| | | Group Art Unit 1764 |

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR § 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:

the fee as set forth in § 1.17(p), or
 the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

37 CFR § 1.97(d)

The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

Legible copies of the references are enclosed when required.

This application is a:

- Continuation / Divisional,
- Continuation-in-Part,

of U.S.S.N. _____ Copies of the cited references are enclosed; not enclosed. References are available in the parent application(s) if not enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

August 24, 2004

Date

Kelly A. Nowak

Kelly A. Nowak
Registration No. 35,620
ExxonMobil Chemical Company
Law Technology
P.O. Box 2149
Baytown, Texas 77522-2149
(281) 834-0341 Voice
(281) 834-2495 Facsimile

FORM - 1449

SHEET 1 OF 1

| INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> | | PATENT DOCUMENT NUMBER | | SERIAL NUMBER | | | |
|--|-----------------|------------------------|-----------------|-----------------|----------|--|--|
| | | 2003B126 | | 10/720,607 | | | |
| | | APPLICANT | | NAME | | | |
| | | Lowe et al. | | | | | |
| FILING DATE | | PRIORITY GROUP | | | | | |
| 11/24/03 | | 1764 | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| AA | 3,651,167 | 03/21/72 | Rosset | 260 | 681.5 | | |
| AB | 4,149,961 | 04/17/79 | Antos | 208 | 139 | | |
| AC | 4,420,420 | 12/13/83 | Mita et al. | 502 | 261 | | |
| AD | 5,364,998 | 11/15/94 | Sarrazin et al. | 585 | 259 | | |
| AE | 5,965,481 | 10/12/99 | Durand et al. | 502 | 304 | | |
| AF | 6,255,548 | 07/03/01 | Didillon et al. | 585 | 259 | | |
| AG | 2002/0068843 | 06/06/02 | Dai et al. | 585 | 260 | | |
| AH | | | | | | | |
| AI | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | DOCUMENT NUMBER | PUBL DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> | |
| AJ | EP 0 261 785 | 03/30/88 | Europe | B01J | 23/62 | | |
| AK | EP 0 624 399 | 11/17/94 | Europe | B01J | 23/76 | X | |
| AL | | | | | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages or Publication, Etc.) | | | | | | | |
| AM | | | | | | | |
| AN | | | | | | | |
| AO | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comment to applicant | | | | | | | |